|This Slide: #59 of 100|
Slide #59. Retrophin — Manchester Pharmaceuticals
Retrophin, Inc. (NASDAQ:RTRX) today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.
Retrophin is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with rare diseases. Co. sells the following three products: Chenodal® (chenodeoxycholic acid), which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age; Cholbam® (cholic acid), which is for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders; and Thiola® (tiopronin), which is for the prevention of cystine (kidney) stone formation in patients with homozygous cystinuria.
RTRX SEC Filing Email Alerts Service
Open the RTRX Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 83% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite